Dr. Chuck Silberstein is a well-educated leader in the finance and healthcare fields. He earned his Doctor of Medicine from the Albert Einstein College of Medicine and an MBA in finance from Columbia. This combination gives him a unique perspective...

Dr. Chuck Silberstein is a well-educated leader in the finance and healthcare fields. He earned his Doctor of Medicine from the Albert Einstein College of Medicine and an MBA in finance from Columbia. This combination gives him a unique perspective in the pharmaceutical industry. Before joining Applied Therapeutics as Chief Financial Officer in 2020, he worked with major companies like Allergan and J.P. Morgan. In his time at Applied Therapeutics, he was granted a significant stock option award in 2020 valued at over $6 million when it vested, and he received notable bonuses for his performance. His expertise helped steer the company through various financial complexities. Dr. Silberstein’s tenure lasted until early 2022, but his experiences and insights have left a lasting impact.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Applied Therapeutics CEOs

A

Dr. Chuck Silberstein

Ex-CEO of Applied Therapeutics

Education

Master of Business Administration in finance from Columbia University and a Doctor of Medicine from the Albert Einstein College of Medicine

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1970 - 55 years ago

CEO of Applied Therapeutics for

1 year 8 months (May 2020 - Jan 2022)

Previous Experience

Senior Vice President of Corporate Business Development at Allergan plc, Executive Director, Senior healthcare analyst for J.P. Morgan Asset Management, Senior Healthcare Analyst at The Boston Company Asset Management, Healthcare Analyst at Goldman Sachs Asset Management

Rivals

Competitors/colleagues of Dr. Chuck Silberstein

Holdings

See how much did Dr. Chuck Silberstein make over time.

Dr. Silberstein's financial portfolio reflected his role at Applied Therapeutics. In 2020, he was awarded options valued at around $6 million which played a big part in shaping his financial standing. His stock position peaked during his time with the...

Dr. Silberstein's financial portfolio reflected his role at Applied Therapeutics. In 2020, he was awarded options valued at around $6 million which played a big part in shaping his financial standing. His stock position peaked during his time with the company, showcasing the volatility but also the potential wealth tied to his role. Although he stepped down in January 2022, he had a solid grounding in equity through the options awarded to him, illustrating how executives can leverage their roles for financial growth. His ability to navigate the market was critical, and his holdings represented a significant portion of his wealth when he was active in the company.

Total Stock Sold

$111.54K

APLT

$111.54K

5,047 APLT shares

What if they kept their stock?

If Dr. Chuck Silberstein didn't sell their stock, today they would have:
Extra APLT5,047 shares worth $208.59K.
This is 87.01% and $97.05K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Chuck Silberstein.

APLT

47,900 shares

APLT

Jan 7, 2022

Received

APLT

47,900 shares

APLT

Dec 14, 2021

Received

APLT

47,900 shares

APLT

Dec 14, 2021

Received

APLT

$108.11K

APLT at $21.42/share

Jun 8, 2021

Sale

APLT

61,000 shares

APLT

Jun 4, 2020

Received

Compensation History

See how much did Dr. Chuck Silberstein make over time.

In 2022, Dr. Silberstein's total compensation, which combined his base salary and bonuses, added up to about $813,473. His salary of $588,473 reflected the competitive nature of executive pay in the pharmaceutical sector. That year, he also received a performance-based bonus of $225,000, split evenly between cash and restricted stock units, highlighting how executive compensation often follows both individual and company performance metrics. But looking back at 2020, he earned significantly more, with total compensation reaching nearly $9 million, primarily due to a high value of vested stock options worth about $6.3 million at that time. This sharp increase underscores the financial rewards in high-stakes roles within the pharmaceutical industry.

Year

2022

Total Compensation

$813.47K

Salary

$588.47K

Board Justification

The compensation philosophy is designed to align the interests of executives with those of stockholders, focusing on performance and retention strategies.

Bonus

$225.00K

Board Justification

Dr. Shendelman received a bonus for 2022 performance, payable in equal parts cash and RSUs vested in full as of the date of grant. A total of $225,000 of this bonus is payable in cash, 50% (representing $112,500) of which was paid in January 2023, and the remaining 50% (representing $112,500) of which will be paid on or about June 30, 2023.

Other

$0.00

Board Justification

No other compensation is reported for 2022.

Restricted Stock

$0.00(0 RSU)

Board Justification

No vested stock is reported for 2022 as the RSUs granted in early 2023 will be included in the 2023 compensation report.

Performance Metrics

The performance metrics for the CEO's compensation include individual performance, company performance, and other relevant factors as determined by the compensation committee.

Other Applied Therapeutics CEOs

Here are other CEOs of Applied Therapeutics

Catherine Thorpe

Ex-CEO of Applied Therapeutics

June 2023 - April 2024